INHIBRX BIOSCIENCES, INC. Increase (Decrease) in Other Noncurrent Assets
INHIBRX BIOSCIENCES, INC. (INBX) reported Increase (Decrease) in Other Noncurrent Assets of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $0.00.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $22.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other noncurrent assets for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other noncurrent assets for fiscal 2024 was $3.67M.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other noncurrent assets for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $22.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $22.00K derived: sum of 3 quarters · filed 2026-05-14 | $28.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $22.00K derived: sum of 2 quarters · filed 2026-03-19 | $28.00K derived: sum of 3 quarters · filed 2026-08-13 | $0.00 10-K · filed 2026-03-19 |
| 2025-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $28.00K derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-14 | $119.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$22.00K 10-Q · filed 2026-08-13 | $97.00K derived: sum of 3 quarters · filed 2026-08-13 | $64.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$28.00K 10-Q · filed 2026-05-14 | $91.00K derived: sum of 2 quarters · filed 2026-05-14 | $58.00K derived: sum of 3 quarters · filed 2026-05-14 | $2.22M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $86.00K derived: sum of 2 quarters · filed 2026-03-19 | $2.25M derived: sum of 3 quarters · filed 2026-03-19 | $3.67M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.13M derived: sum of 2 quarters · filed 2025-11-14 | $3.55M 10-Q · filed 2025-11-14 | $3.55M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.58M 10-Q · filed 2025-08-13 | $3.58M derived: sum of 3 quarters · filed 2025-08-13 | $3.58M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.42M 10-Q · filed 2025-05-14 | $1.42M derived: sum of 2 quarters · filed 2025-05-14 | $1.42M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $0.00 10-K · filed 2025-03-17 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |